Werewolf Therapeutics (NASDAQ:HOWL) Given New $6.00 Price Target at Wedbush

Werewolf Therapeutics (NASDAQ:HOWL) had its price target trimmed by Wedbush from $8.00 to $6.00 in a report released on Friday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other equities analysts also recently issued reports on the company. JMP Securities lowered their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 14th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research report on Wednesday, March 12th.

Werewolf Therapeutics Stock Down 8.1%

Shares of NASDAQ HOWL opened at $0.80 on Friday. The company has a 50 day simple moving average of $0.95 and a 200 day simple moving average of $1.42. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. Werewolf Therapeutics has a 1 year low of $0.60 and a 1 year high of $5.73. The firm has a market cap of $35.89 million, a PE ratio of -0.52 and a beta of 0.48.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.04. Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%. On average, research analysts forecast that Werewolf Therapeutics will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. D. E. Shaw & Co. Inc. bought a new stake in shares of Werewolf Therapeutics in the 4th quarter valued at $26,000. Vontobel Holding Ltd. acquired a new stake in Werewolf Therapeutics in the first quarter worth $34,000. Regal Investment Advisors LLC increased its stake in Werewolf Therapeutics by 88.1% in the fourth quarter. Regal Investment Advisors LLC now owns 27,204 shares of the company’s stock valued at $40,000 after purchasing an additional 12,745 shares in the last quarter. Levin Capital Strategies L.P. acquired a new position in shares of Werewolf Therapeutics during the fourth quarter valued at about $74,000. Finally, Jane Street Group LLC raised its holdings in shares of Werewolf Therapeutics by 261.2% during the fourth quarter. Jane Street Group LLC now owns 54,713 shares of the company’s stock valued at $81,000 after purchasing an additional 39,564 shares during the period. 64.84% of the stock is currently owned by institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.